Background: Breast cancer (BC) is the most common neoplasm in women, with 5%-
Results:
The panel described here allowed identification of several sequence variations in most investigated genes, among which we found a novel truncating mutation in PALB2.
Conclusions:
The NGS-based strategy designed here for molecular analysis of a customized panel of BC predisposing and related genes was found to perform effectively, providing a comprehensive exploration of all genomic sequences of the investigated genes. It is thus useful for BC molecular diagnosis, in particular for familiar cases where alterations in routinely investigated genes, such as BRCAs, result to be absent.
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| INTRODUC TI ON
Breast cancer (BC) is the most common cancer affecting women. In 5%-10% of cases, a familial predisposition is found, up to 1/5th due to germline mutations in the BRCA1/BRCA2 genes. 1 Women carrying BRCA mutations have a cumulative risk of 57%-65% of developing BC by 70 years, in case of BRCA1, and 45%-57% in case of BRCA2 mutations. 2 Female BRCA mutation carriers also have an increased risk of developing ovarian cancer, with a cumulative risk by 70 years of 39%-59% for BRCA1 and of 11%-18% for BRCA2 carriers, respectively.
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Furthermore, BRCA1/BRCA2 carrier males have an increased risk of breast and prostate cancer. 4 Genetic counseling and BRCA gene test are thus commonly recommended for BC patients with early onset, or with a significant family history, and their relatives.
Sequence variants in BRCA1 and BRCA2 genes characterized so far can be classified in three broad classes: single-nucleotide changes, small insertion or deletion events (indels), and large genomic rearrangements (LGRs) occurring in proximity of Alu elements. 5 BRCA2
gene contains less Alu sequences, which may explain how fewer rearrangements have been reported for this gene. 6 Other non-BRCA genes, such as ATM, BRIP1, PALB2, PTEN, and CHEK2, are reported to be medium-to-high-penetrance susceptibility genes associated with hereditary BC. The BC risk for female PALB2 mutation carriers ranges from 33%
(95% CI, 25-44) for those with no family history of BC to 58% (95% CI, 50-66) for those with a family history. 11 Given the growing number of genes involved in BC predisposition, comprehensive multiple gene sequencing in each single case is increasingly required to identify predisposing genetic factors.
Sanger sequencing is still considered the "gold standard" method in the diagnostic field, but next-generation sequencing (NGS) is rapidly becoming a robust and effective alternative approach, thanks to its higher performance, increasing reliability and decreasing costs. Today, this technology is widely used for a variety of clinical genetic tests, including cell-free DNA analysis for noninvasive prenatal testing, wholeexome sequencing (WES), and targeted multigene panel sequencing for complex diseases, such as for example cardiomyopathies, epilepsy, congenital muscular dystrophy, and X-linked intellectual disability. 12, 13 The DNA damage response is a key pathway for the control of cell functions both in physiological and pathological conditions. Recently, PARP is a family of proteins with enzymatic scaffolding properties and recruiting ability for additional proteins required for DNA repair. 14 PARP1 and PARP2, in particular, are critical for the function of base excision repair (BER). PARPis are mainly used for ovarian cancer therapy and are increasingly considered also against BRCA mutation-associated and triple-negative BCs, as sensitizers to DNA damaging chemotherapy. 15 In addition, the use of inhibitory drugs is likely to be extended in the future also to target other mutated genes involved in DNA repair machinery. A necessary prerequisite, however, is the identification of the mutational spectra of several such genes in breast and other cancers. 
| MATERIAL AND ME THODS

| Samples
Samples from 34 patients and four cell lines were analyzed in total.
Human samples derived from breast cancer patients observed from 1980 to 2012 at the Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy. All patients were screened for family history of cancer and referred to the genetic counseling service conducted according to the model previously described. 16 All the patients included in this retrospective analysis provided their informed consent in the framework of cancer genetic counseling program regulated and approved by the Local Ethic committee (University "Federico II" of Naples, Prot. 80/00 and 63/02).
Samples were obtained in accordance with Declaration of Helsinki.
A blood EDTA sample was collected from each subject and genomic DNA was isolated from peripheral blood using either the Purity of DNA was assessed by spectrophotometry using 
| Targeted capture library preparation and sequencing
Library preparation was performed with Illumina Nextera Rapid Custom Capture Enrichment (NRCCE) protocol, using our custom panel designed to test 27 genes involved in DNA repair pathways, including BRCA1/BRCA2 and PARP1/PARP2 (Table S1 ). The Nextera Rapid Capture Custom Enrichment panel was designed using the Illumina Design Studio sequencing assay design tool; 50 ng genomic DNA was used as input and libraries were generated with the Nextera Rapid Capture Enrichment protocol, according to the manufacturer's instructions. Briefly, DNA samples were simultaneously tagmented by the Nextera transposome and ligated to sequencing adapters. Dual Nextera sequencing indices were then attached to each of the tagmented samples by amplification. Samples were then normalized and pooled for sequencing, such that each library contained 500 ng of each uniquely indexed sample. Then, two consecutive hybridizations were performed, the first one lasting 2 hours and a second one overnight (up to 15 hours) using custom oligonucleotide probes. Libraries were captured using streptavidin-conjugated magnetic beads, and a second PCR amplification was performed. 
| PCR and Sanger sequencing of PALB2 exon 12
For validation of the newly identified PALB2 c.3231delC mutation, Sanger sequencing of both DNA strands of the region of interest was performed, using the following primer pairs (same as for the PCR reaction): 5′-agcctatcggtcattgcttt -3′ (forward) and 5′-agggaatctggggtttgact -3′ (reverse) for exon 12. PCR was performed by FastStart Taq DNA Polymerase kit (Roche Life Science, Indiana, USA), and sequencing was carried out with a CEQ2000XL DNA analysis system apparatus (Beckman) by the Molecular Biology Service of Stazione Zoologica "Anton Dohrn" (Naples, Italy).
| Bioinformatic analysis
Demultiplexing, FASTQ files generation, and alignment against the reference were performed with BWA software. Data were then processed with GATK's Unified Genotyper for variant calling to generate VCF files (variant files), which were further filtered and annotated against dbSNP (version 137 in this study).
Data were then analyzed with the optimized pipeline Isaac Enrichment App v2.1 from the Illumina's cloud genomics platform (https://basespace.illumina.com). Alignment was made against the human reference sequence build GRCh37/Hg19. Finally, the variant files were analyzed by VariantStudio Analysis software for annotation and filtering of the generated variants. Only passing filter data and read depth ≥50 were taken into account.
| RE SULTS
Thirty-four patients, selected as previously described, 17 Table S1 . On average, the sequence of selected genes was covered between 1700-fold and 2500-fold. Globally, the designed test led to the identification of about 40 gene sequence variations, as detailed in Table S2 , most of them being already described as BC predisposing ones, including all those previously identified in the same patients by Sanger sequencing of BRCA1 and BRCA2. In particular, we first evaluated sequence quality at the BRCA loci, finding 15 known variations in different patients. These were confirmed with independent tests performed by NGS with the TruSeq Custom amplicon kit and by Sanger sequencing (data not shown). Interestingly, among the several variations identified in the tested genes, a novel mutation in PALB2 gene (c.3231delC; p.Cys1078ValfsTer17) was found in one patient.
The mutation occurs within exon 12 and causes a premature stop codon, with a deleterious effect of gene activity as predicted by
MutationTaster tool. 18 The mutation was confirmed by Sanger sequencing ( Figure 1 ).
| D ISCUSS I ON
Cancer is a condition with significant genetic heterogeneity, for which NGS-based testing has been demonstrated to be an efficient analytical method, as it allows simultaneous sequence analysis of multiple loci of interest in a single reaction. 19 Indeed, commercial diagnostic panels for cancer, most of them investigating genes correlated with Lynch syndrome, cancerous syndromes, and other cancer types (such as kidney, pancreas, and colon), are already available for use in the clinical setting.
Two major high-penetrance genes, BRCA1 and BRCA2, are involved in hereditary BC and when mutated raise the risk also of ovarian, and possibly other, cancer. When a family history of BC is present, it is conceivable to believe that a person has inherited a mutated gene linked to higher BC risk. [20] [21] [22] For this reason, nowadays, genetic testing for screening and/or diagnostic purposes is widely used.
As new genes predisposing to BC are constantly being found, including also several ones involved in DNA damage repair, (Table S2 ). For example, we found the XRCC1 rs1799782 (7 patients) with a prediction of damaging effects on gene function (SIFT, score 0, and Polyphen, score 0.995) but with no clinical annotation in the dbSNP database.
Interestingly, this variant has been described to be associated with the response to platinum-based neoadjuvant chemotherapy in patients with cervical cancer.
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Another drug response variant, found in 15 of the cases analyzed here, is TP53 rs1042522, that has been reported to represent independently minor, but cumulatively significant, increased risk for breast and endometrial cancer. The GG genotype is more likely resistant to first-line chemotherapy in nonsmall cell lung cancer, in particular to the irinotecan plus cisplatin regimen, than CG or CC genotypes (60% vs 27%, P = .014). In addition, GG and CG genotypes were significantly correlated with a lower response rate (and worse progression) to a combination chemotherapy in gastric cancer, when compared to rs1042522 (CC) homozygotes (35.7 vs 66.7%, P-value 0.019). 25, 26 One patient carried the c.1366G>A transition in TERF2 (p. (1 of 34 cases).
More interestingly, we found a new truncating mutation in PALB2 gene (c.3231delC) in one patient suffering with familiar BC but lacking BRCA1 or BRCA2 gene mutations ( Figure 1 and Table   S2 ). Interestingly, the BC risk for PALB2 mutation carriers may overlap that of BRCA2 mutation carriers. The genetic analysis of PARP1 and PARP2 genes on a higher number of patients, as well as identification of somatic mutations of these genes in cancer biopsies-both possible with the assay described here-will help clarify these key issues, thereby improving the clinical management of patients carrying such variations. The importance of testing DNA repair pathway genes to assess the clinical relevance of PARPis as targeted therapy is confirmed also by the fact that a clinical trial concerning the possible use of olaparib in cancer patients with genetic defects in DNA repair genes has been recently approved as is underway (NCT03375307). Patients eligible for this trial should present pathogenic variations in one or more DNA repair genes, most of which, including PALB2, can be analyzed with the assay described here. 
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